BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea (OSA) are growing in prevalence in the USA. Existing data on the relationship between OSA and NAFLD are conflicting and limited by the use of various histologic definitions of nonalcoholic steatohepatitis (NASH). Using a robust definition of NASH in a large, well-characterized cohort, we sought to evaluate whether OSA was associated with NASH and advanced fibrosis. METHODS: Two hundred and thirteen subjects undergoing weight loss surgery were queried for OSA and then underwent liver biopsy. NASH was defined, as recommended by the American Association for the Study of Liver Disease, by the presence of all of the following: >5 % macrovesicular steatosis, lobular inflammation, and hepatocyte ballooning. NAFLD activity score (NAS) was also determined for each subject. RESULTS: Subjects with OSA had significantly higher alanine and aspartate aminotransferase levels than subjects without OSA (ALT 54.1 vs. 37.7 U/L, P = 0.0007; AST 31.7 vs. 20.5 U/L, P = 0.0007). OSA was associated with the presence of NASH, and this remained significant after adjusting for age, gender, race, and diabetes mellitus (P = 0.03 OR 2.01; 95 %, 1.05-3.87). Steatosis grade, lobular inflammation grade, NAS score, and fibrosis stage were all significantly associated with the presence of OSA and remained so after adjustment. CONCLUSIONS: OSA is associated with elevated aminotransferase levels, the presence of NASH, and advanced NASH histology. Further studies are needed to evaluate the impact of OSA treatment on NASH.
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea (OSA) are growing in prevalence in the USA. Existing data on the relationship between OSA and NAFLD are conflicting and limited by the use of various histologic definitions of nonalcoholic steatohepatitis (NASH). Using a robust definition of NASH in a large, well-characterized cohort, we sought to evaluate whether OSA was associated with NASH and advanced fibrosis. METHODS: Two hundred and thirteen subjects undergoing weight loss surgery were queried for OSA and then underwent liver biopsy. NASH was defined, as recommended by the American Association for the Study of Liver Disease, by the presence of all of the following: >5 % macrovesicular steatosis, lobular inflammation, and hepatocyte ballooning. NAFLD activity score (NAS) was also determined for each subject. RESULTS: Subjects with OSA had significantly higher alanine and aspartate aminotransferase levels than subjects without OSA (ALT 54.1 vs. 37.7 U/L, P = 0.0007; AST 31.7 vs. 20.5 U/L, P = 0.0007). OSA was associated with the presence of NASH, and this remained significant after adjusting for age, gender, race, and diabetes mellitus (P = 0.03 OR 2.01; 95 %, 1.05-3.87). Steatosis grade, lobular inflammation grade, NAS score, and fibrosis stage were all significantly associated with the presence of OSA and remained so after adjustment. CONCLUSIONS: OSA is associated with elevated aminotransferase levels, the presence of NASH, and advanced NASH histology. Further studies are needed to evaluate the impact of OSA treatment on NASH.
Authors: Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri Journal: Hepatology Date: 2011-02-11 Impact factor: 17.425
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Arun J Sanyal; Elizabeth M Brunt; David E Kleiner; Kris V Kowdley; Naga Chalasani; Joel E Lavine; Vlad Ratziu; Arthur McCullough Journal: Hepatology Date: 2011-07 Impact factor: 17.425
Authors: Vladimir Savransky; Ashika Nanayakkara; Angelica Vivero; Jianguo Li; Shannon Bevans; Philip L Smith; Michael S Torbenson; Vsevolod Y Polotsky Journal: Hepatology Date: 2007-04 Impact factor: 17.425
Authors: Steven R Coughlin; Lynn Mawdsley; Julie A Mugarza; Peter M A Calverley; John P H Wilding Journal: Eur Heart J Date: 2004-05 Impact factor: 29.983
Authors: Vladimir Savransky; Shannon Bevans; Ashika Nanayakkara; Jianguo Li; Philip L Smith; Michael S Torbenson; Vsevolod Y Polotsky Journal: Am J Physiol Gastrointest Liver Physiol Date: 2007-08-09 Impact factor: 4.052
Authors: Peter Benotti; G Craig Wood; George Argyropoulos; Allan Pack; Brendan T Keenan; Xiang Gao; Glenn Gerhard; Christopher Still Journal: Obesity (Silver Spring) Date: 2016-02-16 Impact factor: 5.002
Authors: Salvatore Petta; Oreste Marrone; Daniele Torres; Maria Buttacavoli; Calogero Cammà; Vito Di Marco; Anna Licata; Anna Lo Bue; Gaspare Parrinello; Antonio Pinto; Adriana Salvaggio; Antonino Tuttolomondo; Antonio Craxì; Maria Rosaria Bonsignore Journal: PLoS One Date: 2015-12-16 Impact factor: 3.240